Aerpio Pharmaceuticals, Inc. (ARPO) Income Statement Analysis

See more : São Martinho S.A. (SMTO3.SA) Income Statement Analysis – Financial Results

Complete financial analysis of Aerpio Pharmaceuticals, Inc. (ARPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aerpio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Aerpio Pharmaceuticals, Inc. (ARPO)

Industry: Biotechnology

Sector: Healthcare

Website: http://www.aerpio.com

About Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.

Metric	2022	2021	2020	2019	2018	2017
Revenue	5.51M	4.47M	823.00K	0.00	0.00	0.00
Cost of Revenue	35.02M	20.02M	14.44M	8.32M	0.00	0.00
Gross Profit	-29.51M	-15.54M	-13.62M	-8.32M	0.00	0.00
Gross Profit Ratio	-535.75%	-347.36%	-1,655.04%	0.00%	0.00%	0.00%
Research & Development	35.02M	20.02M	14.44M	9.82M	15.14M	12.75M
General & Administrative	7.44M	8.28M	7.97M	8.16M	2.52M	2.71M
Selling & Marketing	0.00	0.00	0.00	1.50M	1.40M	1.37M
SG&A	7.44M	8.28M	7.97M	9.67M	3.92M	4.08M
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	7.44M	7.56M	7.96M	10.32M	15.93M	15.33M
Cost & Expenses	42.45M	27.57M	22.40M	18.64M	15.93M	15.33M
Interest Income	29.00K	59.00K	600.00K	835.00K	768.00K	202.00K
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	892.00K	1.17M	1.11M	1.35M	1.35M	1.53M
EBITDA	-36.05M	-22.65M	-20.47M	-16.64M	-9.54M	-13.92M
EBITDA Ratio	-654.58%	-506.33%	-2,487.61%	0.00%	0.00%	0.00%
Operating Income	-36.95M	-23.82M	-21.59M	-17.99M	-10.89M	-15.46M
Operating Income Ratio	-670.77%	-532.45%	-2,622.96%	0.00%	0.00%	0.00%
Total Other Income/Expenses	29.00K	667.00K	-594.00K	-1.49M	-5.81M	330.00K
Income Before Tax	-36.92M	-23.16M	-22.18M	-19.48M	-16.70M	-15.13M
Income Before Tax Ratio	-670.24%	-517.55%	-2,695.14%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-36.92M	-23.16M	-22.18M	-19.48M	-16.70M	-15.13M
Net Income Ratio	-670.24%	-517.55%	-2,695.14%	0.00%	0.00%	0.00%
EPS	-1.08	-0.96	-1.35	-2.43	-3.59	-2.25
EPS Diluted	-1.08	-0.96	-1.35	-2.43	-3.59	-2.25
Weighted Avg Shares Out	34.29M	24.10M	16.42M	7.64M	4.65M	6.74M
Weighted Avg Shares Out (Dil)	34.29M	24.10M	16.42M	8.01M	4.65M	6.74M

Spreading ‘Biden fever’: John Phillips

July 30, 2020presstelegram.com

If the Progressive Turnout Project wants Democrats to turn out, they’re going to have to rely on “Biden Fever.”

The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs

July 24, 2020benzinga.com

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Acceleron Pharma Inc (NASDAQ: XLRN) Aerpio...